Loading...
XSTOTOL
Market cap14mUSD
Dec 23, Last price  
0.58SEK
1D
-1.02%
1Q
19.18%
Jan 2017
-88.92%
IPO
-92.24%
Name

Toleranzia AB

Chart & Performance

D1W1MN
XSTO:TOL chart
P/E
—
P/S
3.11
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
56.24%
Rev. gr., 5y
64.11%
Revenues
51m
+43.98%
6,227,6583,164,972309,00466,0103,631,0262,532,3304,277,8836,949,43712,881,50027,589,00035,367,00050,920,000
Net income
-7m
L-11.79%
40,19638,959-737,223-4,109,695-5,055,571-5,391,991-5,657,963-9,929,020-4,894,585-6,283,865-8,456,000-7,459,000
CFO
-6m
L-12.18%
00-935,224-3,361,268-5,251,146-5,605,743-4,822,947-4,432,966-3,991,297-6,849,365-7,200,000-6,323,000

Profile

Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. In addition, the company develops tolerogens technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases. The company was founded in 2011 and is headquartered in Gothenburg, Sweden.
URL
https://www.toleranzia.com/
IPO date
Dec 16, 2015
Employees
14
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
50,920
43.98%
35,367
28.19%
27,589
114.18%
Cost of revenue
51,839
(35,257)
2,695
Unusual Expense (Income)
NOPBT
(919)
70,624
24,894
NOPBT Margin
199.69%
90.23%
Operating Taxes
(17,076)
35
Tax Rate
0.14%
NOPAT
(919)
87,700
24,860
Net income
(7,459)
-11.79%
(8,456)
34.57%
(6,284)
28.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
43,378
69,532
BB yield
-76.13%
-83.76%
Debt
Debt current
Long-term debt
850
850
850
Deferred revenue
Other long-term liabilities
(850)
Net debt
(17,454)
(33,087)
(75,428)
Cash flow
Cash from operating activities
(6,323)
(7,200)
(6,849)
CAPEX
(35,141)
(26,314)
Cash from investing activities
(50,778)
(35,141)
(26,314)
Cash from financing activities
41,468
66,291
FCF
(894)
87,670
24,876
Balance
Cash
18,304
33,937
76,278
Long term investments
Excess cash
15,758
32,169
74,899
Stockholders' equity
(30,876)
(34,261)
(25,805)
Invested Capital
185,244
154,620
154,620
ROIC
56.72%
19.89%
ROCE
58.68%
19.33%
EV
Common stock shares outstanding
133,133
110,315
70,351
Price
0.43
-61.79%
1.12
-5.08%
1.18
-22.62%
Market cap
56,981
-53.88%
123,553
48.83%
83,014
85.81%
EV
39,527
90,466
7,586
EBITDA
(894)
70,641
24,910
EV/EBITDA
1.28
0.30
Interest
95
19
35
Interest/NOPBT
0.03%
0.14%